Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post a loss of $0.43 per share when it actually produced a loss of $0.3, delivering a surprise of +30.23%.Over the last four quarters, the company has s ...

Alpha Cognition (NasdaqCM:ACOG) Q4 2025 Earnings call March 26, 2026 04:30 PM ET Company ParticipantsDave Storms - Director of Equity ResearchHenry Du - Interim CFOLauren D'Angelo - COOMichael McFadden - CEOConference Call ParticipantsRam Selvaraju - Managing Director and Senior Healthcare AnalystOperatorGreetings. Welcome to Alpha Cognition fourth quarter and full year 2025 Earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presenta ...

Alpha Cognition (NasdaqCM:ACOG) Q4 2025 Earnings call March 26, 2026 04:30 PM ET Company ParticipantsDave Storms - Director of Equity ResearchHenry Du - Interim CFOLauren D'Angelo - COOMichael McFadden - CEOConference Call ParticipantsRam Selvaraju - Managing Director and Senior Healthcare AnalystOperatorGreetings. Welcome to Alpha Cognition fourth quarter and full year 2025 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presenta ...

Alpha Cognition (NasdaqCM:ACOG) Q4 2025 Earnings call March 26, 2026 04:30 PM ET Speaker4Greetings. Welcome to Alpha Cognition fourth quarter and full year 2025 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to Henry Du ...

Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update Alpha Cognition generated fourth quarter 2025 ZUNVEYL net product revenue of $2.5 million, contributing to full year 2025 total revenue of $10.2 million Exhibit 99.1 Alpha Cognition Inc. Nasdaq: ACOG 1452 Hughes Road, Ste. 200 Grapevine, TX 65051 www.alphacognition.com info@alphacognition.com Fourth quarter bottles dispensed increased 62% quarter-over-quarter to 4,941, with December representing the strongest month si ...

Core Viewpoint - Alpha Cognition Inc. is set to report its fourth quarter and full year 2025 financial results on March 26, 2026, and will provide a business update during a conference call [1]. Financial Results Announcement - The company will issue a press release detailing its financial results and business highlights on March 26, 2026, after market close [1]. - A conference call will follow the release to review financial and operating results, scheduled for 4:30 PM ET [1]. Product Development and Clinical Studies - Alpha Cognition is focused on developing treatments for neurodegenerative diseases, including Alzheimer's disease and cognitive impairment associated with mild traumatic brain injury (mTBI) [1]. - The company’s drug ZUNVEYL® is a new generation acetylcholinesterase inhibitor with minimal gastrointestinal side effects, targeting neuronal nicotinic receptors [1]. - Alpha Cognition is also developing ALPHA-1062 in combination with memantine for moderate to severe Alzheimer's dementia and as an intranasal formulation for cognitive impairment with mTBI [1]. Upcoming Presentations and Studies - The company will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists conference in April 2026 and the Neuroscience Education Institute Spring Congress in May 2026 [2]. - Alpha Cognition announced the enrollment of the first patient in the BEACON Phase 4 real-world effectiveness study to assess ZUNVEYL's impact in long-term care settings [2]. Patent Developments - The United States Patent and Trademark Office has issued a new patent covering dosing regimens for ZUNVEYL, enhancing the company's intellectual property portfolio [2].

Group 1 - Alpha Cognition Inc. (ACOG) is a stock in the Medical sector, which includes 950 individual stocks and has a Zacks Sector Rank of 4 [2] - ACOG currently holds a Zacks Rank of 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - Over the past three months, the Zacks Consensus Estimate for ACOG's full-year earnings has increased by 30%, reflecting improved analyst sentiment [4] Group 2 - Year-to-date, ACOG has returned approximately 8.2%, outperforming the average gain of 6.5% for Medical stocks [4] - ACOG belongs to the Medical - Biomedical and Genetics industry, which consists of 467 stocks and is currently ranked 91 in the Zacks Industry Rank [6] - Stocks in the Medical - Biomedical and Genetics industry have gained an average of 19.9% this year, indicating that ACOG is slightly underperforming its industry [6] Group 3 - Actinium Pharmaceuticals (ATNM) is another Medical stock that has outperformed the sector with a year-to-date increase of 15.1% [5] - The consensus estimate for Actinium Pharmaceuticals' current year EPS has risen by 11.7% over the past three months, and it also holds a Zacks Rank of 2 (Buy) [5] - The Medical - Drugs industry, to which Actinium Pharmaceuticals belongs, has moved up by 7.9% this year and is currently ranked 79 [7]

Group 1 - The event is a fireside chat featuring Michael McFadden, CEO of Alpha Cognition, and Boris Peaker, Head of Research and Managing Director at Titan Partners [1][2] - The format encourages a conversational atmosphere, allowing attendees to engage by submitting questions in the chat [1]

Summary of Alpha Cognition Fireside Chat - December 02, 2025 Company Overview - **Company**: Alpha Cognition (NasdaqCM: ACOG) - **Product**: ZUNVEYL, targeting the long-term care market for Alzheimer's patients - **Market Size**: Approximately $2.2 billion for long-term care related to Alzheimer's disease [5][6] Key Performance Metrics - **Sales**: Reported $2.3 million in sales for Q3 2025 [5] - **Key Performance Indicators (KPIs)**: - Physician prescribing and repeat orders - Nursing home orders and repeat orders - Adherence rates between 5 mg and 10 mg doses - Payer metrics, including plans covered and lives covered without restriction [5] Market Penetration and Adoption - **Target Market**: Approximately 5,000 specialized nursing homes in the U.S. [6] - **Current Adoption**: - 600 nursing homes have written prescriptions; 550 homes wrote orders in Q3 [6] - 60% refill or reorder rate in homes contacted [6] - 576 healthcare providers (HCP) writers in Q3, approaching 700 since launch [6] - **Payer Contracts**: Currently one contract covering 15% of lives; a second contract anticipated soon [10] Product Utilization - **Dosage Distribution**: 50% of patients on 5 mg and 50% on 10 mg; expected to shift to 75% on 10 mg at steady state [11] - **Pricing**: Flat pricing of $820 WAC per month for all doses; gross-to-net expected to stabilize at $500 in three years [13][15] Stakeholder Engagement - **Key Stakeholders**: - Medical directors (primary customers) - Psychiatrists (treat behavioral symptoms) - Directors of nursing (first to observe symptoms) - Consultant pharmacists (make treatment recommendations) [20][21] - **Messaging**: Focus on lower GI incidents and no insomnia with ZUNVEYL compared to competitors [22][24] Clinical Development - **Ongoing Trials**: - **Converge Trial**: Retrospective analysis of ZUNVEYL in long-term care; results expected in Q3 2026 [42][45] - **Beacon Trial**: Real-world evidence study assessing cognition and behavior in 200 patients; completion expected by end of 2026 [49] - **Resolve Trial**: Phase four observational trial in outpatient settings; expected to provide label-enabling data [64][68] International Strategy - **China Market**: Approximately 10 million patients; submission accepted in July 2025, with potential approval by late 2026 [95][96] - **Economic Model**: Milestone payments and high single-digit royalties from Asian markets; no marketing costs for Alpha Cognition [98] Financial Guidance - **Operating Profitability**: Expected in 2027, excluding non-cash items like depreciation [101] - **R&D Spending**: Anticipated to be $50 million-$55 million in 2026, with a decrease expected in 2027 due to fewer ongoing clinical studies [105][108] Additional Insights - **Sublingual Formulation**: Development underway to address patient difficulties in swallowing; estimated market opportunity of $200 million [69][70] - **Department of Defense Study**: Completed a bomb blast study showing positive cognitive effects; potential for IND submission for cognitive impairment in mild traumatic brain injury [88][89] This summary encapsulates the key points discussed during the fireside chat, highlighting Alpha Cognition's market strategy, product performance, clinical development, and financial outlook.

Core Viewpoint - Alpha Cognition Inc. is actively engaging in commercialization efforts and research initiatives to enhance the adoption of its therapies for neurodegenerative diseases, particularly through participation in a virtual fireside chat hosted by Titan Partners [1][2]. Company Overview - Alpha Cognition Inc. is a commercial-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including Alzheimer's disease and cognitive impairment associated with mild traumatic brain injury (mTBI) [2][9]. - The company is dedicated to addressing the unmet medical needs in these areas, where currently no approved treatment options exist [2]. Product Information - ALPHA-1062, marketed as ZUNVEYL, is an FDA-approved new generation acetylcholinesterase inhibitor designed for the treatment of Alzheimer's disease, with minimal gastrointestinal side effects expected [3]. - ZUNVEYL's active metabolite uniquely binds to neuronal nicotinic receptors, particularly the alpha-7 subtype, which is associated with cognitive enhancement [3]. - The product is also being developed in combination with memantine for moderate to severe Alzheimer's dementia and as a sublingual formulation for cognitive impairment with mTBI [3]. Upcoming Events - Alpha Cognition will participate in a virtual fireside chat on December 2, 2025, featuring CEO Michael McFadden, focusing on commercialization strategies and research initiatives [2]. - The company is set to report its third quarter 2025 financial results and provide a business update on November 13, 2025, after market close [9].